What Is MDMA-Assisted Therapy?

MDMA-assisted therapy pairs pharmaceutical-grade MDMA with structured psychotherapy across three supervised dosing sessions over approximately 12 weeks. Each session runs 6 to 8 hours with two trained therapists present. The model uses preparation and integration therapy around each dosing day. In Canada, legal patient access is limited to Health Canada authorization granted on a case-by-case basis, initiated by a physician and considered primarily for adults with PTSD.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-27.

Key takeaways

• MDMA-assisted therapy uses pharmaceutical-grade MDMA in a structured three-session clinical model. It is not the same as recreational "ecstasy" or "molly," which are illicit-market products of unknown composition.
• Three dosing sessions at 6 to 8 hours each over approximately 12 weeks; standard dose 80 mg with an optional 40 mg booster approximately 90 minutes later (Mitchell 2021 MAPP1 protocol).
• MDMA is not a classic psychedelic. The mechanism is serotonin and norepinephrine release plus significant oxytocin release, not 5-HT2A partial agonism (the psilocybin/LSD mechanism). The experience is emotional warmth and relational openness, not visual disturbance or ego dissolution.
• Amygdala reactivity drops during the dosing window, creating what clinicians call a "fear-extinction window," a therapeutic state in which patients can engage with traumatic content without becoming overwhelmed.
• Two therapists are present during each dosing session. Patients remain conversationally available throughout; active trauma-focused therapeutic work happens during the session itself.
• The MAPS Phase 3 evidence base (MAPP1 and MAPP2, both published in Nature Medicine) provides the strongest clinical foundation for MDMA-AT in PTSD available to date.
• In Canada, legal access requires Health Canada authorization on a case-by-case basis, initiated by a physician, and is not guaranteed. ATMA CENA does not administer MDMA. Its role in relation to MDMA-assisted therapy is preparation and integration support, including partnering with an appropriately trained therapist through the CoCare program.

If you are researching MDMA-AT and want to understand whether it could be relevant for your situation, book a free 15-minute information call. ATMA CENA's clinical team will walk through preparation specific to your circumstances.

How MDMA works in the brain

MDMA produces its therapeutic effects through several neurotransmitter systems acting together. The combination is what makes the therapeutic state distinctive, and different from every other psychedelic-assisted therapy modality.

Serotonin release and the distinction from classic psychedelics

MDMA reverses the function of the serotonin transporter (SERT), causing serotonin to flood synaptic spaces rather than be reuptaken into the presynaptic neuron. The result is a large increase in synaptic serotonin within roughly 30 to 60 minutes of dosing, producing mood elevation and emotional openness.

This mechanism is fundamentally different from classic psychedelics: psilocybin and LSD work primarily as 5-HT2A receptor partial agonists, producing perceptual changes and ego dissolution. MDMA's serotonin-release mechanism produces emotional warmth and connectedness without the perceptual disturbance that characterises classic psychedelic experience.

Norepinephrine and dopamine release

MDMA also releases norepinephrine and dopamine. These contribute to elevated alertness and reward-related effects. The norepinephrine release is responsible for the increases in heart rate and blood pressure observed during dosing, a meaningful point for pre-treatment cardiovascular screening.

Oxytocin release and the trust window

One of MDMA's most therapeutically significant mechanisms is significant oxytocin release. Oxytocin is the neuropeptide associated with social bonding, trust, attachment, and reduced social fear. The oxytocin effect is implicated in the emotional warmth, reduced fear of vulnerability, and increased capacity for relational openness that define the MDMA therapeutic state.

For trauma populations, the oxytocin-mediated reduction in fear of attachment appears to deepen the therapeutic alliance during the dosing window. Patients can engage emotionally with both the therapist team and with traumatic content in ways that conventional pharmacotherapy or talk therapy alone does not always enable.

Amygdala reactivity and the fear-extinction window

Multiple neuroimaging studies have shown that MDMA dampens amygdala response to threat cues during the dosing window. The amygdala is hyperreactive in PTSD; reduced amygdala reactivity allows patients to engage with traumatic content without becoming overwhelmed by fear, dissociation, or autonomic arousal.

This dampened fear response, combined with the oxytocin-mediated trust window, is what clinicians refer to as the "fear-extinction window": a state in which patients can process traumatic material therapeutically without the memory consolidating again at peak distress.

Prefrontal regulation of fear circuits

Emerging neuroimaging evidence suggests MDMA-AT enhances prefrontal regulation of amygdala fear circuits in ways that translate into lasting PTSD symptom reduction over the post-dosing weeks. The working mechanistic account: acute amygdala dampening plus oxytocin-mediated relational opening allows therapeutic processing to occur during the session; post-dosing prefrontal-amygdala reorganisation consolidates the gains.

The honest framing: the mechanism is plausible and supported by converging evidence, but specifics remain active research. The clinical evidence from the MAPP1 and MAPP2 Phase 3 trials is what establishes the therapeutic effect; the mechanism is the explanatory framework still being refined.

The three-session clinical model

Standard MDMA-AT follows a three-phase structure across three dosing sessions, based on the Mitchell 2021 (MAPP1) and Mitchell 2023 (MAPP2) MAPS protocols.

Phase 1: Preparation (3 sessions before the first dose)

Preparation sessions build the foundation for safe and effective dosing:

• Therapeutic alliance with the dosing team. Most published trial protocols use the same therapist pair throughout all phases. The therapists who will be present during all three dosing sessions meet the patient in advance.
• Personal and trauma history review. Trauma-focused work benefits from understanding what has already been processed and what has not.
• Set and setting orientation. Music preview; what to expect on dosing day; how to navigate moments of acute distress; the 6-to-8-hour session structure.
• Medication-specific informed consent covering the authorization pathway, expected effects, known risks, and contraindications.
• Safety planning. Post-dosing rest day, the 24-hour no-driving rule, emergency contact protocols.

Phase 2: Dosing days (3 sessions over approximately 12 weeks)

Three dosing sessions, typically spaced 3 to 5 weeks apart. Each dosing day follows this structure:

• Morning: arrival, vitals, settling in, dose administration (typically 80 mg MDMA orally; optional 40 mg booster approximately 90 minutes after the first dose).
• Onset (30 to 60 minutes after dose): emerging effects, emotional warmth, mild body sensations.
• Peak (1.5 to 3 hours after first dose): maximum intensity. Patients typically remain conversationally available. This is not the inward-focused experience of psilocybin or the dissociated experience of ketamine. Therapists can engage in active trauma-focused work during this window.
• Plateau (3 to 5 hours): sustained therapeutic state.
• Comedown (5 to 7 hours): gradual return.
• Discharge (7 to 8 hours): vitals; brief debrief; companion driver pickup.
• Overnight monitoring in some protocols (particularly MAPS Phase 3): patient stays at clinic overnight after the first dose.

The active therapeutic engagement during dosing is the key difference from psilocybin, where therapists are predominantly quiet and non-directive during the session. MDMA's experiential profile, in which patients remain emotionally engaged and conversational, supports active trauma-focused exchange throughout the dosing window.

Phase 3: Integration (3 sessions after each dosing day)

After each MDMA dosing session, three integration sessions over the following weeks. Across a full three-session course, that is 9 integration sessions total, plus 3 preparation sessions and 3 dosing days, substantially more clinical contact than psilocybin protocols.

Integration work includes:

• Meaning-making of what surfaced during dosing
• Continued trauma-focused processing of material begun during the session
• Behavioural commitments relevant to PTSD recovery (relationships, daily functioning, routines)
• Monitoring for and addressing symptom resurgence

What patients typically experience during a dosing session

The MDMA state differs from every other psychedelic-assisted modality:

Emotional and relational:

• Emotional warmth and openness. Many patients describe feeling unusually connected, generous, and undefended.
• Reduced fear of vulnerability; willingness to discuss content that would normally feel too threatening to approach.
• Increased empathy for self and others.
• A sense of safety even when engaging directly with traumatic content.

Cognitive:

• Conversational availability. Patients typically remain able to talk, reflect, and narrate. This is fundamentally different from the inward-focused psilocybin state or the dissociated ketamine state.
• Clarity about life patterns, relationships, and internal experiences.
• Reduced rumination during the dosing window.

Physical:

• Elevated heart rate and blood pressure, typically 10 to 20% above baseline. Pre-treatment cardiovascular screening matters.
• Body temperature elevation; rooms are kept cool and hydration is monitored.
• Pupil dilation.
• Jaw tension or clenching; addressed with mouth guards in some protocols.
• Mild nausea during onset for some patients.

Limited perceptual changes: Unlike classic psychedelics, MDMA does not typically produce significant visual changes, hallucinations, ego dissolution, or mystical-type experiences. The altered state is emotional and relational rather than perceptual.

How MDMA-AT differs from psilocybin and ketamine therapy

The three psychedelic-assisted therapy modalities differ in mechanism, experiential profile, and clinical structure:

	MDMA-AT	Psilocybin therapy	Ketamine therapy
Primary indication	PTSD	End-of-life distress; TRD; AUD	TRD; PTSD; chronic pain
Sessions per program	3	1 to 2	4 to 8 (IV); 12 (Spravato)
Session length	6 to 8 hours	6 to 8 hours	90 to 120 minutes (IV)
Total clinical contact	~24 sessions	~7 to 10 sessions	~10 to 14 sessions
Mechanism	5-HT/NE release + oxytocin	5-HT2A partial agonism	NMDA antagonism
Experiential profile	Emotional warmth, conversational, reduced fear	Classic psychedelic: visuals, ego dissolution, mystical	Dissociative: body softening, time distortion
Therapist activity during dosing	Active conversational engagement	Predominantly quiet, non-directive	Monitoring presence and grounding

Pharmaceutical MDMA versus recreational "ecstasy"

This distinction is essential and parallels the pharmaceutical-psilocybin versus recreational-mushroom distinction:

	Pharmaceutical MDMA	Recreational "ecstasy" or "molly"
Source	Synthetic MDMA manufactured under GMP standards by licensed manufacturers for authorized clinical and trial use	Illicit market; frequently adulterated with methamphetamine, caffeine, novel psychoactive substances
Composition	Pure MDMA at known concentration	Variable, often NOT pure MDMA
Dose precision	Exact (e.g., 80 mg per capsule, verified)	Highly variable; potency unknown
Regulatory status in Canada	Schedule I; legal therapeutic access only through case-by-case Health Canada authorization	Schedule I; illegal recreational possession
Setting	Monitored clinical facility; two trained therapists; screened patients	Variable; unmonitored

Street "ecstasy" or "molly" is not MDMA-AT and is not a substitute for it. Clinical MDMA-AT uses pharmaceutical-grade MDMA only, in a supervised clinical setting, under Health Canada authorization granted on a case-by-case basis. The pharmacological, safety, and legal frameworks are entirely different.

The Phase 3 evidence base

The clinical evidence for MDMA-AT in PTSD is built on two landmark Phase 3 trials published in Nature Medicine:

MAPP1 (Mitchell et al., 2021): Randomized, double-blind, placebo-controlled Phase 3 trial (n = 90; 42 MDMA completers, 37 placebo completers). At 18 weeks: 67% of the MDMA-AT group no longer met DSM-5 PTSD criteria versus 32% of the placebo group (Cohen's d = 0.91; p less than 0.0001). The effect size is notably large. [Mitchell 2021; PMID 33972795]

MAPP2 (Mitchell et al., 2023): Confirmatory Phase 3 trial (n = 104; 53 MDMA-AT, 51 placebo). At end of treatment: 71.2% of the MDMA-AT group no longer met DSM-5 PTSD criteria versus 47.6% of the placebo group (Cohen's d = 0.7; p less than 0.001). Remission rates were 46.2% versus 21.4%. [Mitchell 2023; PMID 37709999]

Earlier Phase 2 work established foundational safety and efficacy data. Mithoefer et al. (2018) reported significant PTSD symptom reduction in a Phase 2 dose-response RCT in 26 veterans, firefighters, and police officers [Mithoefer 2018; PMID 29728331]. Mithoefer et al. (2010) found that 83% of MDMA-AT recipients versus 25% of placebo recipients no longer met PTSD criteria after treatment in the first MAPS Phase 2 trial (n = 20) [Mithoefer 2010; PMID 20643699].

What the evidence means (and does not mean): The Phase 3 data is exceptionally strong for a PTSD intervention. It does not mean MDMA-AT is guaranteed to work for any individual. Response remains individualized and depends on clinical history, the quality of the therapeutic work, and individual variation. No outcome promises are made here or by the trial authors.

FDA and regulatory context: The FDA issued a Complete Response Letter to Lykos Therapeutics on August 8, 2024, declining to approve MDMA-AT for PTSD. The FDA cited concerns about blinding integrity (MDMA's distinctive subjective effects create expectancy bias), data gaps, and trial-conduct concerns at certain sites, and requested an additional Phase 3 trial. Lykos committed to a new Phase 3 trial. In Canada, case-by-case access continues independently of the FDA decision, and any future Canadian approval timeline remains uncertain.

Eligibility and screening

Most published MDMA-AT trials and Canadian case-by-case authorization requests use these criteria. A qualified prescribing physician makes eligibility determinations for individual patients.

Generally eligible:

• Adults aged 18 or older
• DSM-5 PTSD diagnosis with documented adequate prior treatment (trauma-focused CBT, prolonged exposure, EMDR; SSRIs or SNRIs at therapeutic dose for at least 6 weeks)
• Medically stable; able to provide informed consent

Absolute contraindications:

• Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I)
• Current or recent mania or hypomania
• Uncontrolled cardiovascular disease; recent myocardial infarction; severe structural heart disease; significant arrhythmia
• Pregnancy
• Severe hepatic impairment
• Concurrent MAOIs (serotonin syndrome and hypertensive crisis risk)

Relative contraindications:

• Active substance use disorder (typical exclusion in trial protocols)
• Active high-dose serotonergic antidepressants, typically tapered before MDMA dosing under prescriber supervision; SSRIs may also attenuate MDMA's therapeutic effect through serotonergic adaptation
• Severe personality disorder with marked instability
• Complex trauma without adequate therapeutic alliance or preparation capacity

Frequently asked questions

Is MDMA-AT a classic psychedelic experience?

No. MDMA's mechanism is serotonin and norepinephrine release plus oxytocin release, not 5-HT2A partial agonism like psilocybin or LSD. The experience is emotional warmth and relational openness, not visual disturbance or ego dissolution. Patients typically remain conversationally available throughout the session.

How is pharmaceutical MDMA different from "ecstasy"?

Pharmaceutical MDMA is the pure compound at a known concentration, manufactured under GMP standards, used in a controlled clinical setting with two trained therapists and medical supervision. "Ecstasy" or "molly" is an illicit-market product that frequently contains methamphetamine, caffeine, novel psychoactive substances, or other adulterants and is not MDMA-AT.

How many sessions are in a course of MDMA-AT?

Three dosing sessions over approximately 12 weeks, plus 3 preparation sessions before the first dose, plus 3 integration sessions after each dosing day (9 integration sessions in total). Total clinical contact across the full course is approximately 24 sessions, substantially more than psilocybin or ketamine protocols.

What does a dosing session feel like?

Emotional warmth, increased connection, reduced fear of vulnerability, conversational availability, increased empathy. Patients typically remain able to engage in active trauma-focused work throughout the 6 to 8 hour session. The state is not characterised by visual hallucinations or ego dissolution.

Why are two therapists present?

MAPS-supported protocols use two therapists for several reasons: continuity across the 6 to 8 hour session; therapist-patient matching (some protocols use a male-female dyad for relational trauma reasons); safety redundancy; and active relational engagement during the therapeutic window.

Can I drive after a session?

No. A 24-hour no-driving rule applies after every dosing session. Some protocols require an overnight stay at the clinic after the first dose for additional monitoring.

What about cardiovascular effects?

MDMA typically raises heart rate and blood pressure approximately 10 to 20% above baseline during dosing. Pre-treatment cardiovascular screening is a required part of the clinical intake. Uncontrolled hypertension, recent myocardial infarction, severe structural heart disease, and significant arrhythmia are absolute contraindications.

I am on an SSRI. Does that affect anything?

SSRIs typically attenuate MDMA's therapeutic effect through serotonin-system adaptation. Most trial protocols taper SSRIs before MDMA dosing under prescriber supervision. Concurrent MAOIs are an absolute contraindication due to the risk of serotonin syndrome and hypertensive crisis.

Is MDMA-AT addictive?

Pharmaceutical MDMA in a supervised three-session clinical protocol does not create the exposure conditions associated with dependence development. The regulatory framework prohibits take-home dispensing. Recreational chronic high-dose MDMA use carries different risks and is a separate discussion.

How does MDMA-AT compare to psilocybin therapy for PTSD?

Different mechanism, different experiential profile, more clinical sessions, longer total program. MDMA-AT has the strongest Phase 3 trial evidence specifically in PTSD. Psilocybin has the strongest evidence in treatment-resistant depression and end-of-life distress.

Can my regular therapist work with me?

Through ATMA CENA's CoCare program, it can be possible. CoCare partners with your existing therapist when they hold the appropriate training and build a service agreement with ATMA CENA. Your therapist must also hold the regulated professional authorization to deliver psychotherapy in your province. In Quebec, Bill 21 reserves the practice of psychotherapy to physicians, psychologists, and OPQ-permit holders, so your existing therapist must meet that requirement. The information call is the right place to determine whether your specific situation is a fit.

Where can I access MDMA-AT in Canada?

Legal access requires Health Canada authorization initiated by a physician and granted on a case-by-case basis. Because approval is not guaranteed, the practical starting point is a conversation with your primary care physician or psychiatrist about whether a request is appropriate for your situation. Organizations such as MAPS Canada and TheraPsil publish patient-facing resources on the pathway.

Compliance disclaimer

MDMA is a Schedule I controlled substance under Canada's Controlled Drugs and Substances Act. It has no Notice of Compliance in Canada and is not approved for general medical use. Legal patient access to MDMA-assisted therapy is available only through Health Canada authorization, which permits a licensed physician to apply on behalf of a patient with a serious condition when other treatments have failed or are unavailable. Each request is evaluated on a case-by-case basis, and approval is not guaranteed. In practice, this pathway has been considered primarily for adults with PTSD.

ATMA CENA does not administer MDMA and does not file these applications. ATMA CENA's psychedelic-assisted therapy program is built on ketamine, and its role in relation to MDMA-assisted therapy is limited to preparation and integration support, including partnering with an appropriately trained therapist through its CoCare program.

This article is educational and does not constitute medical or clinical advice. Clinical decisions belong with a qualified prescribing physician. Nothing in this article should be construed as a recommendation for a specific individual.

Health Canada guidance on requests for psychedelic-assisted psychotherapy

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6), 1025–1033. PMID 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
2. Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10), 2473–2480. PMID 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
3. Mithoefer MC, et al. (2018). Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after MDMA-assisted psychotherapy: a prospective long-term follow-up study. Lancet Psychiatry. PMID 29728331. https://pubmed.ncbi.nlm.nih.gov/29728331/
4. Mithoefer MC, et al. (2010). The safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder. Journal of Psychopharmacology. PMID 20643699. https://pubmed.ncbi.nlm.nih.gov/20643699/
5. Sessa B, Higbed L, Nutt D. (2019). A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Frontiers in Psychiatry, 10:138. PMID 30949077. https://pubmed.ncbi.nlm.nih.gov/30949077/
6. Danforth AL, et al. (2018). MDMA-assisted therapy for social anxiety in autistic adults. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/28205155/
7. Health Canada. Requests for psychedelic-assisted psychotherapy (case-by-case access pathway). https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
8. Government of Canada. MDMA / Ecstasy. https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/mdma.html
9. ATMA CENA. Information Call. https://atmacena.com/information-call/

Related articles in this cluster

• CoCare Model

---

Last updated: 2026-05-27. Evergreen educational content, scheduled review every 6 months.